Applied dna customer Úhkt initiates phase i clinical trial for rapidly manufacturable car t-cell therapy produced from linea dna

- regulatory approval showcases clinical advancement of linea dna™ as a rapid and effective means of producing car-t cell therapies - stony brook, ny / accesswire / december 18, 2024 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, announced that the state institute for drug control of the czech republic (sÚkl) approved an application for a phase i clinical trial of an investigational cd123-specific autologous car t-cell therapy by the institute of hematology and blood transfusion (Úhkt/eng: ihbt) in prague for the treatment of relapsed and/or refractory acute myeloid leukemia (aml). uhkt-car123-01 utilizes applied dna's synthetic dna, linea™ dna, as a critical component in its manufacture.
APDN Ratings Summary
APDN Quant Ranking